Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access

A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context

Deals Business Strategies

Jubilant Sees No Material Impact From Coronavirus-Led Plant Closure, For Now

Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.

Commercial Coronavirus COVID-19

Aurobindo-Sandoz End $1bn US Deal

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Commercial Deals

Takeda Gets New India Chief, Mandate To Broaden Access

Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.

Commercial Appointments

Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath

China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.

Deals Research and Development Strategies

Otsuka Dermatitis Candidate Looks Good At Phase III

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.

Japan Clinical Trials
See All

Europe

Set Alert for Europe

Latest From Europe

Spanish Biotechs Join Battle Against COVID-19

Spain has suffered more than most from COVID-19 but the life sciences sector is exploring a variety of ways to tackle the coronavirus pandemic.

Coronavirus COVID-19 Spain

Shifting EU Treatment Paradigms In CLL

The CLL market segment in the EU will now include a first-line combination therapy of AbbVie’s venetoclax and Roche’s obinutuzumab, which has recently been approved by the European Commission.

Cancer Approvals

Coronavirus Update: Europe Enters Lockdown, Pharma Home Working, Belldegrun Tests Positive

Governments around Europe take action to shut places of work and schools and impose new border restrictions, as death toll rises in Italy, France and Spain.

Europe Companies

CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

Coronavirus COVID-19 Companies

All Aboard The Biotech Train: AstraZeneca Campus Gets Connected

The new Cambridge South station should be ready by 2025, serving AstraZeneca’s new HQ and leading hospitals and research institutes.

Commercial Companies

LSP Closes Mega Life Sciences Fund For Europe, But US Still Way Ahead

A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.

StartUps and SMEs Financing
See All

United States

Set Alert for United States

Latest From United States

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Legal Issues Intellectual Property

US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle

South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.

South Korea United States

CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

Coronavirus COVID-19 Companies

High-Priced Entries Drive 17% Rise In Spending On Anti-Inflammatory Drugs

But declines in other categories held overall spending on US retail pharmacy drugs covered by commercial plans to a marginal 2.3% increase in 2019, Express Scripts reports.

Pharmacy Benefit Management Reimbursement

Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions

Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.

Advisory Committees Drug Review

How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

Vaccines Pricing Debate
See All
UsernamePublicRestriction

Register